Oxcarbazepine – place in the treatment of epilepsy Review article
Article Sidebar
Published:
Mar 31, 2021
Keywords:
oxcarbazepine, focal seizures, efficacy, safety, drug interactions, sexual dysfunction, depressive disorders
Main Article Content
Abstract
Oxcarbazepine is recommended for the first line treatment of focal seizures in monotherapy and add-on therapy in both children and adults. It is well tolerated and less frequently interacts with other drugs, possible side effects less often lead to the cessation of the therapy. An important feature of the drug is a positive effect on the sexual sphere of patients and a presumed positive effect on reducing depressive symptoms.
Article Details
How to Cite
Kopka, M. (2021). Oxcarbazepine – place in the treatment of epilepsy. Medycyna Faktow (J EBM), 14(1(50), 98-101. https://doi.org/10.24292/01.MF.0121.13
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Schachter SC, Vazquez B, Fisher RS et al. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology. 1999; 52: 732-7.
2. Sachdeo R, Beydoun A, Schachter S et al. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology. 2001; 57(5): 864-71.
3. Rov T, Biswas A. Oxcarbamazepine, the new effective anti-epileptic drug for add-on as well as monotherapy in partial epilepsies. J Indian Med Assoc. 2002; 100(5): 336.
4. Koch MW, Polman SK. Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. Cochrane Database Syst Rev. 2009; (4). Art No. CD006453.
5. Nevitt SJ, Marson AG, Weston J et al. Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev. 2018, Issue 10. Art. No. CD003615.
6. Kanner AM, Ashman E, Gloss D et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018; 91(2): 74‐81.
7. Jędrzejczak J, Majkowska-Zwolińska B, Ryglewicz D et al. Zalecenia Polskiego Towarzystwa Epileptologii dotyczące leczenia napadów padaczkowych u dorosłych. Aktualizacja. J Epileptol. 2019; 27: 5-12.
8. NICE: 2004, 2018.
9. Abou-Khalil BW. Update on Antiepileptic Drugs 2019. Continuum (Minneap Minn). 2019; 25(2): 508-36.
10. Berghuis B, van der Palen J, de Haan GJ et al. Carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy. Epilepsia. 2017; 58(7): 1227‐33.
11. Lu X, Wang X. Hyponatremia induced by antiepileptic drugs in patients with epilepsy. Expert Opinion on Drug Safety 2016. http://doi.org/10.1080/14740338.2017.1248399.
12. Mazurkiewicz-Bełdzińska M, Czuczwar S. Leki przeciwpadaczkowe. In: Białecka M, Sławek J. Interakcje leków w neurologii. Via Medica, Gdańsk 2015: 161-98.
13. Veroniki AA, Cogo E, Rios P et al. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Med. 2017; 15: 95.
14. Campbell E, Kennedy F, Russell A et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry. 2014; 85: 1029-34.
15. Hernandez-Diaz S, Smith CR, Shen A et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012; 78: 1692-9.
16. Tomson T, Battino D, Bonizoni E et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018; 17(6): 530‐8.
17. Baker GA, Bronley RL, Briggs M et al. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology. 2015; 84(4): 382-90.
18. US Food and Drug Administration. FDA drug safety communication: valproate anti-seizure products contraindicated for migraine prevention in pregnant women due to decreased IQ scores in exposed children. June 5, 2013 (accessed Sept 12, 2017).
19. European Medicines Agency. Assessment report: procedure under article 31 of directive 2001/83/EC resulting from pharmacovigilance data. Oct 9, 2014 (accessed April 10, 2015).
20. Herzog AG. Disorders of reproduction in patients with epilepsy: primary neurological mechanisms. Seizure. 2008; 17: 101-10.
21. Braun M, Wassmer G, Klotz T et al. Epidemiology of erectile dysfunction: results of the Cologne Male Survey. Int J Impot Res. 2000; 12: 305-11.
22. Herzog AG. Reproductive endocrine regulation in men with epilepsy: effects on reproductive function and neuronal excitability. Ann Neurol. 2002; 51: 539-42.
23. Mattson RH, Cramer JA. Epilepsy, sex hormones, and antiepileptic drugs. Epilepsia. 1985; 26(suppl. 1): 40-51S.
24. Luef G, Krämer G, Stefan H. Oxcarbazepine treatment in male epilepsy patients improves pre-existing sexual dysfunction. Acta Neurol Scand. 2009; 119(2): 94‐9.
25. Tellez-Zenteno JF, Patten S, Williams J et al. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia. 2007; 48(12): 2336‐44.
26. Jobe PC. Common pathogenetic mechanisms between depression and epilepsy: an experimental perspective. Epilepsy Behav. 2003; 4: S14-24.
27. Jones JE, Hermann BP, Woodard JL et al. Screening for major depression in epilepsy with common self-report depression inventories. Epilepsia. 2005; 46: 731-5.
28. Mazza M, Della Marca G, Di Nicola M et al. Oxcarbazepine improves mood in patients with epilepsy. Epilepsy Behav. 2007; 10397-401.
2. Sachdeo R, Beydoun A, Schachter S et al. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology. 2001; 57(5): 864-71.
3. Rov T, Biswas A. Oxcarbamazepine, the new effective anti-epileptic drug for add-on as well as monotherapy in partial epilepsies. J Indian Med Assoc. 2002; 100(5): 336.
4. Koch MW, Polman SK. Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. Cochrane Database Syst Rev. 2009; (4). Art No. CD006453.
5. Nevitt SJ, Marson AG, Weston J et al. Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev. 2018, Issue 10. Art. No. CD003615.
6. Kanner AM, Ashman E, Gloss D et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018; 91(2): 74‐81.
7. Jędrzejczak J, Majkowska-Zwolińska B, Ryglewicz D et al. Zalecenia Polskiego Towarzystwa Epileptologii dotyczące leczenia napadów padaczkowych u dorosłych. Aktualizacja. J Epileptol. 2019; 27: 5-12.
8. NICE: 2004, 2018.
9. Abou-Khalil BW. Update on Antiepileptic Drugs 2019. Continuum (Minneap Minn). 2019; 25(2): 508-36.
10. Berghuis B, van der Palen J, de Haan GJ et al. Carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy. Epilepsia. 2017; 58(7): 1227‐33.
11. Lu X, Wang X. Hyponatremia induced by antiepileptic drugs in patients with epilepsy. Expert Opinion on Drug Safety 2016. http://doi.org/10.1080/14740338.2017.1248399.
12. Mazurkiewicz-Bełdzińska M, Czuczwar S. Leki przeciwpadaczkowe. In: Białecka M, Sławek J. Interakcje leków w neurologii. Via Medica, Gdańsk 2015: 161-98.
13. Veroniki AA, Cogo E, Rios P et al. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Med. 2017; 15: 95.
14. Campbell E, Kennedy F, Russell A et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry. 2014; 85: 1029-34.
15. Hernandez-Diaz S, Smith CR, Shen A et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012; 78: 1692-9.
16. Tomson T, Battino D, Bonizoni E et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018; 17(6): 530‐8.
17. Baker GA, Bronley RL, Briggs M et al. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology. 2015; 84(4): 382-90.
18. US Food and Drug Administration. FDA drug safety communication: valproate anti-seizure products contraindicated for migraine prevention in pregnant women due to decreased IQ scores in exposed children. June 5, 2013 (accessed Sept 12, 2017).
19. European Medicines Agency. Assessment report: procedure under article 31 of directive 2001/83/EC resulting from pharmacovigilance data. Oct 9, 2014 (accessed April 10, 2015).
20. Herzog AG. Disorders of reproduction in patients with epilepsy: primary neurological mechanisms. Seizure. 2008; 17: 101-10.
21. Braun M, Wassmer G, Klotz T et al. Epidemiology of erectile dysfunction: results of the Cologne Male Survey. Int J Impot Res. 2000; 12: 305-11.
22. Herzog AG. Reproductive endocrine regulation in men with epilepsy: effects on reproductive function and neuronal excitability. Ann Neurol. 2002; 51: 539-42.
23. Mattson RH, Cramer JA. Epilepsy, sex hormones, and antiepileptic drugs. Epilepsia. 1985; 26(suppl. 1): 40-51S.
24. Luef G, Krämer G, Stefan H. Oxcarbazepine treatment in male epilepsy patients improves pre-existing sexual dysfunction. Acta Neurol Scand. 2009; 119(2): 94‐9.
25. Tellez-Zenteno JF, Patten S, Williams J et al. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia. 2007; 48(12): 2336‐44.
26. Jobe PC. Common pathogenetic mechanisms between depression and epilepsy: an experimental perspective. Epilepsy Behav. 2003; 4: S14-24.
27. Jones JE, Hermann BP, Woodard JL et al. Screening for major depression in epilepsy with common self-report depression inventories. Epilepsia. 2005; 46: 731-5.
28. Mazza M, Della Marca G, Di Nicola M et al. Oxcarbazepine improves mood in patients with epilepsy. Epilepsy Behav. 2007; 10397-401.